“Fighter Mom’s” Join Forces

by | Feb 27, 2013 | 0 comments

Is it just coincidence, being in the right place at the right time, or is it synchronicity?  Synchronicity, as defined by Wikipedia: “The idea of synchronicity is that the conceptual relationship of minds, defined as the relationship between ideas, is intricately structured in its own logical way and gives rise to relationships that are not casual in nature.”  Nearly a year ago, Allison Moore, HNF Founder, and Lori Sames, Co-Founder of Hannah’s Hope Fund (HHF), met at the World Orphan Drug Conference in Washington, D.C. when Lori set her plate down on the high cocktail table across from Allison.  From this day forward, Allison and Lori talk as often as they do with their siblings, sometimes even more so!

Lori Sames and her husband Matt formed Hannah’s Hope Fund (HHF) following their youngest daughter’s diagnosis of Giant Axonal Neuropathy (GAN) in 2008. GAN is the most rare, and one of the most severe, forms of Inherited Neuropathy.  GAN is fatal in the late teens or early 20’s.  HHF has funded the development of GAN gene therapy to the central nervous system and hope to begin a Phase 1 trial this year.  The goal is to stop the progression of GAN in the central nervous system.  HHF is also working to discover a small molecule drug to treat the peripheral nerves.  GAN is classified as an inherited neuropathy, similar to some of the forms of CMT Type 2’s, and the cellular models of GAN will eventually be used to help test efficacy of CMT Type 2 candidate therapeutics. Likewise, potential therapeutics discovered for GAN will be tested on CMT Type 2 models.  HNF has developed a CMT Type 2A mouse model which will be used when targets are identified. The reason this collaboration is so critical is because compounds that are discovered to improve axonal transport are likely to be beneficial to most forms of CMT Type 2.  The more disease models we are able to show efficacy in, the greater the likelihood for federal grants and additional therapeutic strategy approaches.Allison & Lori

Recent unpublished data reveal the protein not functioning in GAN, called gigaxonin, directly regulates intermediate filament proteins.  Intermediate filament protein aggregates are implicated in a few forms of CMT, as well as Lou Gehrig’s Disease (ALS).  We are happy to have a new team of scientists collaborating with HNF’s scientific team as we continue to discover more data, identify existing small molecules & vectors and optimize our dollars to cure CMT Type 2.

This year HNF and HHF are co-funding the Global Patient Registry for Inherited Neuropathies, which is clinically focused, unlike existing registries.  The goals of the clinical registry are: collect information and tissue samples needed by the research community; assist in getting patients properly diagnosed with their specific form of inherited neuropathy; and recruitment for clinical trials.

When Allison first me Lori, she drawn to her determination in learning the science and putting the destiny of her daughter and many others in her own hands by demanding treatments and scanning the world for maybe not the obvious. There has to be a way, she said, and “I’m so happy to meet another FM”. “FM?” I asked. Lori explained,  “Fighter Mom’s,” as in mothers with children who are living with these conditions.  Now a year later both Allison and Lori spend countless days and hours meeting scientists, Big Pharma, BioTech, NIH staff, sitting on panels at conferences to share their organizations’ mission, researching business models and the most effective approaches to engaging industry, initiating collaborations, and most importantly, not taking no for an answer. CMT and all other related inherited neuropathies need attention and treatments. These two women are on a mission to cure these diseases!

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news